Background: High-dose chemotherapy (HDT) followed by autologous stem-cell transplantation (ASCT) is considered the gold standard in the treatment of patients with relapsed or refractory Hodgkin's lymphoma (HL). However, the optimal salvage regimen has not yet been established.
introduction
Hodgkin's lymphoma (HL) is a potentially curable disease with standard chemotherapy combinations. However, up to a 10% of patients do not achieve a complete response (CR) with firstline therapy and 20%-40% will suffer a relapse [1] . High-dose chemotherapy (HDT) followed by autologous stem-cell transplantation (ASCT) is currently considered the standard of care for these patients [2, 3] . Two prospective randomized trials showed significant benefit in freedom from treatment failure for ASCT over conventional therapy for relapsed disease [4, 5] . Several retrospective and phase II studies have subsequently shown that ASCT produces 30%-65% long-term disease-free survival in selected patients with relapsed or refractory HL [6] [7] [8] [9] . In all these studies, the strongest prognostic factor has been the sensitivity of the disease to the salvage chemotherapy. Patients with HL who do not achieve CR after salvage chemotherapy have a very poor outcome. Therefore, efforts to identify the best pretransplant salvage chemotherapy regimen, combining therapeutic activity, stem-cell-mobilizing potential, and low toxicity, represent a challenging issue for these patients.
Several pretransplant salvage regimens for refractory or relapsed HL have been developed, usually incorporating drugs not used in initial treatment in an attempt to avoid resistance. These regimens allow an overall response rate (ORR) and CR rate ranging from 60% to 80% and from 17% to 40%, respectively [10, 11] . However, no randomized trials are available comparing the relative efficacy of these different regimens.
The use of an alternating scheme with MINE (mesna, ifosfamide, mitoxantrone, and etoposide) and ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) was the salvage therapy option in our center, on the basis of previous reported experience in relapsing non-Hodgkin lymphomas [12] and the historical utilization of separate MINE or ESHAP regimens in relapsed HL [13, 14] . To our knowledge, there are no published data evaluating this chemotherapy combination in HL. Here, we report a retrospective analysis of the feasibility, safety profile, and efficacy of salvage therapy with alternating MINE-ESHAP in a single center.
patients and methods
patients From 2000 to 2007, 61 patients with refractory or relapsed HL after firstline treatment who were planned to receive MINE-ESHAP regimen followed by HDT and ASCT with curative intention at the Department of Hematology in the Hospital Clínic of Barcelona (Spain) were the subjects of the present study. All patients had biopsy-proven diagnosis of HL and had adequate organ function and performance status. Patients with multiple relapses were excluded. Details of patient characteristics, prior chemotherapy regimens, disease status at diagnosis and at relapse, response rates after salvage chemotherapy, stem-cell harvesting, conditioning regimen previous to ASCT, and follow-up were obtained. 
MINE-ESHAP salvage regimen

assessment of response
Response to therapy was evaluated according to physical examination and computed tomography scans of the thorax and abdomen. Positron emission tomography scanning was available in some patients but not routinely used for all patients during the period of this study. CR was defined as the disappearance of all clinical and radiographic evidence of disease for at least 1 month. Partial response (PR) was defined as a >50% reduction of measurable disease lasting >1 month. Any response less than PR was considered stable disease (SD); increase in size of lesions and/or initial symptoms was labeled as progressive disease (PD). ORR included patients with CR and PR. Response was assessed after MINE-ESHAP and after ASCT.
statistical analysis
Primary end point of the study was response to therapy (CR, PR, and ORR) after MINE-ESHAP treatment. Secondary end points were event-free survival (EFS) and overall survival (OS), defined in accord to previous consensus [15] , and toxicity. Data are presented as descriptive values and percentages or median values and ranges, when appropriate. Univariate logistic regression analysis was used to identify variables that were predictive of response. The variables examined were as follows: sex, age (<45 versus ‡45 years), bulky disease, B symptoms, extranodal involvement, number of involved sites (£3 versus >3), response to first-line chemotherapy (CR or PR versus SD or PD), time to relapse, anemia (hemoglobin <120 g/l for males and <105 g/l for females), and Epstein-Barr virus (positive versus negative). All variables showing a P value <0.1 were considered as candidates for a stepwise logistic regression procedure. The actuarial survival analysis was carried out using the Kaplan-Meier method and the curve comparison by the log-rank test. For data analysis, computerbased statistical package for social sciences for Windows, version 14.0 (SPSS Inc., Chicago, IL) was used.
results
characteristics of the patients
Sixty-one patients (31 female/30 male; median age 36 years, range 18-63) who had not either achieved a CR (PR, n = 13, or refractory disease, n = 17) or relapsed (n = 31) after ABVDbased chemotherapy were included in this study. The main features of the patients at diagnosis are listed in Table 1 . Nodular sclerosis was the most frequent histological subtype (74%) and 24% of the evaluated patients had expression of latent membrane protein-1 in cellular membrane in lymph node biopsy by immunohistochemistry. First-line treatment consisted of ABVD regimen in 42 patients (69%), ABVD alternating with CMOPP (cyclophosphamide, vincristine, procarbazine, and methylprednisolone) in 17 (31%). The median number of cycles was 6.5 (range 4-12). Twenty-two patients (36%) received complementary radiotherapy. After initial therapy, 31 (51%) patients achieved a CR, 13 (21%) a PR, 5 (8%) an SD, and 12 (20%) presented PD. In the group of patients achieving CR, 7 (23%) suffered an early relapse and 24 (77%) relapsed 12 months after first-line treatment (late relapses).
feasibility and toxicity of MINE-ESHAP treatment and PBSC collection
Median number of courses of MINE-ESHAP was 4 (range 1-6). Forty-five patients (74%) received the proposed original scheme (two MINE and two ESHAP). Six patients received five cycles and two patients six cycles according to physician decision. Eight patients received less than four cycles due to etoposide allergic reaction (n = 1), death from acute ischemic stroke (n = 1), and grade 3 infection (n = 6).
Grade 3-4 neutropenia, thrombocytopenia, and anemia occurred in 26 (46%), 23 (40%), and 22 (38%) patients, respectively. Eleven episodes of grade 3 non-hematologic toxic effects were observed: eight infectious events, two impairment of renal function after ESHAP regimen, and one allergic reaction to etoposide. No toxic deaths were seen. There were no differences in the incidence of adverse reaction in patients with relapse or with refractory disease after first-line treatment.
Fifty-eight patients underwent PBSC mobilization with G-CSF (21 patients) or with ESHAP plus G-CSF (37 patients). One patient with persistent pancytopenia received high-dose cytarabine as mobilization regimen. Two patients did not undergo PBSC mobilization due to PD and death not related to the HL treatment, respectively. Adequate PBSC collection was achieved in 57 of 59 (97%) mobilized patients. The median number of collected CD34+ cells after G-CSF mobilization was 3.7 · 10 6 cells/kg (range 0.45-15) after a median of one leukopheresis (range 1-4) and after ESHAP plus G-CSF 4.15 · 10 6 CD34+ cells/kg (range 2.5-21.5)(P = 0.242) after a median of one leukopheresis (range 1-2). Thirty-two patients (54%) reached the target yield of 2 · 10 6 CD34+ cells/kg in first attempt, 15 required two leukopheresis sessions (25%), and the rest three or four sessions. Two relapsed patients who failed PBSC mobilization with G-CSF underwent bone marrow aspiration to complete the target yield of 2 · 10 6 CD34+ cells/kg for ASCT. There were no differences in the number of recollections in patients with relapse or with refractory disease after first-line treatment.
efficacy of MINE-ESHAP and survival analysis
After MINE-ESHAP, 25 patients (41%) achieved a CR, 23 (38%) a PR, 4 (7%) an SD, and 8 (13%) had progression of HL, for an ORR of 79%. In the univariate analysis, the factor showing a significant prognostic value for response to MINE-ESHAP was response to first-line chemotherapy (CR or PR versus SD or PD, P = 0.007). All other prognostic factors, such as age, sex, bulky mass, histological subtype, Epstein-Barr virus presence, clinical stage, B symptoms, number of involved areas, anemia, time to relapse, and extranodal involvement, did not influence the response rate significantly. The response according to HL status after first-line treatment (relapsed after CR, PR, or refractoriness) is showed in Table 2 .
Fifty-nine patients received HDT and ASCT. Two patients did not undergo ASCT because of poor performance status and limiting comorbidities that prevent transplantation, and another patient died of an unrelated disease (massive ischemic ictus). The conditioning regimen consisted of BEAM in 53 patients and BEAC in 6 patients. Two patients died of transplant-related complications (myocarditis and acute respiratory distress syndrome, respectively). In an intention-totreat analysis, ORR increased after ASCT with 48 patients achieving CR and 3 PR for a total of 84% ORR. The 5-year OS and EFS were 68% and 55%, respectively ( Figure 1A and B) . Patients with refractory HL after MINE-ESHAP had significantly lower OS (50% versus 75%; P = 0.005) and EFS (29% versus 63%; P = 0.001) than those with chemosensitivity disease, respectively (Figure 2A and B) . The median follow-up time in patients who were alive at the time of the study was 3.5 years (range 0.5-8.9). Three secondary myelodysplasia and acute myeloid leukemia were observed.
Ten patients relapsing or progressing after ASCT (one PR, two PD, and seven relapses) received allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen (RIC) from a human leukocyte antigen-compatible familiar or unrelated donor. After transplant, two patients died of transplant-related complications, four had HL progression, one achieved a PR, and three are alive in CR 14, 16, and 62 months after allogeneic transplantation. This report describes the results of a retrospective study of alternating MINE-ESHAP regimen followed by HDT and ASCT for patients with relapsed or refractory HL to first-line therapy. Several salvage chemotherapy regimens previous to ASCT in these patients have been reported [2, 3, 13, 14, [16] [17] [18] .
Comparison of results between them is difficult due to the heterogeneity of first-line treatments, in most cases suboptimum regimens not containing ABVD, and the different follow-up, sometimes including only patients who respond to salvage therapy and other including all patients, regardless of additional therapies. Unfortunately, no randomized trial comparing salvage regimens exits, and the choice of secondline chemotherapy must be guided by efficacy and toxicity reported in these single-arm studies and retrospective analysis. Because most patients will proceed to ASCT, a salvage protocol with high response rate and low toxicity should be chosen. Some authors have favored the use of aggressive salvage regimens such as dexa-BEAM or mini-BEAM that results in significant hematological toxicity and a 2%-5% treatmentrelated death rate, similar to those seen with ASCT [6, 19, 20] . Most other centers commonly use regimens based on etoposide, ifosfamide, and/or platinum such as ESHAP, DHAP, MINE, MIME , and ICE [11, 13, 14, 18, 21, 22] . Those regimens have more tolerable toxicity profile and produce an ORR of 60%-80% and CR rate <30%-35%. Recently, new salvage regimens that incorporate gemcitabine have been reported. 
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In the present analysis, MINE-ESHAP induced an ORR of 79%, similar to that reported with previous salvage regimes but with a higher CR rate (41%) even in ABVD-refractory patients (18%). It is noteworthy that CR rate was higher than that observed with DHAP or MINE alone (21% and 34%, respectively) [13, 14] . These results were consolidated with HDT and ASCT in most patients (97%), independently of their response to MINE-ESHAP, reaching a final ORR of 86% and 5-year EFS of 55%. The effect of transplantation was essentially increasing the percentage of CR versus PR in patients with chemosensitivity disease to MINE-ESHAP, together with some CR/PR in refractory patients. It should be remarked that the initial profile of patients was of high risk, with almost half of them (49%) failing to first-line treatment and 23% with an early relapse. In the multivariate analysis, response to first-line chemotherapy was the most important prognostic factor for response to MINE-ESHAP.
Our results are comparable with those recently reported with a new gemcitabine-based salvage scheme [10] . In that prospective trial, 91 patients with refractory or relapsed HL were treated with ifosfamide, gemcitabine, vinorelbine, and prednisolone (IGEV). Forty percent of patients were refractory to previous treatments and four patients had relapsed after HDT and ASCT. A total of 49 patients (54%) achieved a CR and 25 (27%) a PR for an ORR of 81%. Similarly to our results, the authors found that response to the last chemotherapy before IGEV was the main prognostic factor associated to response to salvage treatment. MINE-ESHAP has the advantage to an approved drug combination for this indication and the possibility to save alternatives such as gemcitabine in the case of further HL relapse.
Safety and toxicity of salvage chemotherapy are other relevant factors. The data reported here show that MINE-ESHAP has a manageable toxicity with no treatment-related deaths. Only eight infectious events requiring hospitalization were recorded. These results compare very favorably with other salvage regimens such as mini-BEAM or dexa-BEAM [6, 19, 20] , where a higher incidence of side-effects and treatment-related death was documented. Secondary myelodisplastic syndrome and/or acute myeloid leukemia were diagnosed in three patients, but we cannot relate this effect only to MINE-ESHAP regimen since these patients also underwent HDT and ASCT. To this sense, no patient had received nitrogen mustard.
Another important issue for a pretransplant salvage regimen is its ability to mobilize PBSCs. An adequate PBSC collection was observed in 97% of patients. Although no significant differences were observed between patients receiving ESHAP plus G-CSF as mobilization regimen and those receiving G-CSF alone in the numbers of collected CD34+ cells/kg, the numbers of leukopheresis necessary to achieve the target yield of 2 · 10 6 CD34+ was lower for ESHAP plus G-CSF regimen.
Disease relapse after ASCT remains a significant therapeutic challenge. Recent reports have shown that allogeneic transplantation using RIC regimens has a nonrelapse mortality of 15%-25% and a progression-free survival of 18%-32% [23, 24] . In addition, a number of trials have emphasized the importance of continued sensitivity to chemotherapy before RIC allogeneic transplant, with disease status at transplant (CR or PR) being a very strong predictor of subsequent progression-free survival and OS. In our series, 3 of 10 patients receiving RIC allogeneic transplantation after ASCT are alive in CR, all of them had achieved a CR after second salvage chemotherapy before RIC.
In conclusion, MINE-ESHAP is a safe therapeutic alternative for patients with refractory or relapsed HL who are candidates to HDT and ASCT that combine a high mobilizing potential and a high ORR and CR. Controlled and randomized trials comparing MINE-ESHAP versus conventional salvage therapies, such as MINE or ESHAP alone, or versus new approaches such as IGEV are warranted to clarify the role of these chemotherapy regimens previously to ASCT. 
